Furthermore, silencing of the ARF GEF, GEP100, was found to be an effective strategy to inhibit lung metastasis in mice suggesting that in vivo, ARF GTPases may contribute to the progression of breast cancer [17]. Here, CDKN2A is linked to breast carcinoma.